Corcept Therapeutics Incorporated Stock Beneish M Score

CORT Stock  USD 22.66  0.34  1.48%   
This module uses fundamental data of Corcept Therapeutics to approximate the value of its Beneish M Score. Corcept Therapeutics M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Corcept Therapeutics Piotroski F Score and Corcept Therapeutics Altman Z Score analysis.
  
At this time, Corcept Therapeutics' Long Term Debt Total is comparatively stable compared to the past year. Debt To Equity is likely to gain to 0.0003 in 2024, whereas Short Term Debt is likely to drop slightly above 143.4 K in 2024. At this time, Corcept Therapeutics' ROIC is comparatively stable compared to the past year. Inventory Turnover is likely to gain to 0.88 in 2024, whereas Stock Based Compensation To Revenue is likely to drop 0.1 in 2024.
At this time, it appears that Corcept Therapeutics is an unlikely manipulator. The earnings manipulation may begin if Corcept Therapeutics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Corcept Therapeutics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Corcept Therapeutics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.7
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

1.0

Focus
Asset Quality

1.0

Focus
Expense Coverage

1.0

Focus
Gross Margin Strengs

0.79

Focus
Accruals Factor

1.0

Focus
Depreciation Resistance

1.0

Focus
Net Sales Growth

1.05

Focus
Financial Leverage Condition

1.0

Focus

Corcept Therapeutics Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Corcept Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables57.9 M55.1 M
Sufficiently Up
Slightly volatile
Total Assets652.6 M621.5 M
Sufficiently Up
Slightly volatile
Total Current Assets481.6 M458.6 M
Sufficiently Up
Slightly volatile
Non Current Assets Total171 M162.9 M
Sufficiently Up
Slightly volatile
Property Plant Equipment2.1 MM
Sufficiently Up
Slightly volatile
Depreciation And Amortization2.5 M2.4 M
Sufficiently Up
Slightly volatile
Selling General Administrative193.1 M184.3 M
Sufficiently Up
Slightly volatile
Total Current Liabilities109.7 M104.5 M
Sufficiently Up
Slightly volatile
Short Term Debt143.4 K151 K
Notably Down
Slightly volatile
Gross Profit Margin0.780.9866
Significantly Down
Slightly volatile

Corcept Therapeutics Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Corcept Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Corcept Therapeutics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Corcept Therapeutics' degree of accounting gimmicks and manipulations.

About Corcept Therapeutics Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

2.48 Million

At this time, Corcept Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year.

Corcept Therapeutics Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Corcept Therapeutics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Net Receivables19.9M26.2M27.6M45.1M55.1M57.9M
Total Revenue306.5M353.9M366.0M401.9M482.4M506.5M
Total Assets412.3M571.7M423.8M583.4M621.5M652.6M
Total Current Assets352.6M524.2M381.4M498.7M458.6M481.6M
Net Debt(311.9M)(474.3M)(335.3M)(435.5M)(135.4M)(142.2M)
Operating Income111.6M128.2M124.5M112.6M107.3M112.6M
Investments(116.7M)(118.0M)136.6M(114.3M)56.6M59.4M

About Corcept Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Corcept Therapeutics Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corcept Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corcept Therapeutics Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Corcept Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corcept Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corcept Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Corcept Stock

  0.64DRUG Bright Minds BiosciencesPairCorr
  0.55KA Kineta Inc Financial Report 9th of May 2024 PairCorr
  0.55DRTS Alpha Tau Medical Financial Report 28th of May 2024 PairCorr
  0.54DMTK DermTech Financial Report 2nd of May 2024 PairCorr
  0.48ME 23Andme HoldingPairCorr
The ability to find closely correlated positions to Corcept Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corcept Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corcept Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corcept Therapeutics Incorporated to buy it.
The correlation of Corcept Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corcept Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corcept Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corcept Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Corcept Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Corcept Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Corcept Therapeutics Incorporated Stock. Highlighted below are key reports to facilitate an investment decision about Corcept Therapeutics Incorporated Stock:
Check out Corcept Therapeutics Piotroski F Score and Corcept Therapeutics Altman Z Score analysis.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Corcept Stock analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Money Managers
Screen money managers from public funds and ETFs managed around the world
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Stocks Directory
Find actively traded stocks across global markets
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Commodity Directory
Find actively traded commodities issued by global exchanges
Content Syndication
Quickly integrate customizable finance content to your own investment portal
CEOs Directory
Screen CEOs from public companies around the world
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Is Corcept Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corcept Therapeutics. If investors know Corcept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corcept Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.995
Earnings Share
0.95
Revenue Per Share
4.658
Quarterly Revenue Growth
0.314
Return On Assets
0.1113
The market value of Corcept Therapeutics is measured differently than its book value, which is the value of Corcept that is recorded on the company's balance sheet. Investors also form their own opinion of Corcept Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Corcept Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corcept Therapeutics' market value can be influenced by many factors that don't directly affect Corcept Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corcept Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corcept Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corcept Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.